RT Journal Article
SR Electronic
T1 Outcomes of etonogestrel subdermal contraceptive implants
JF Saudi Medical Journal
JO Saudi Med J
FD Prince Sultan Military Medical City
SP 261
OP 266
DO 10.15537/smj.2024.45.3.20230840
VO 45
IS 3
A1 Shams, Taghreed M.
A1 Alhashemi, Hashem H.
A1 Fallatah, Albaraa A.
A1 Alkhalid, Asma M.
A1 Alhazmi, Fai M.
A1 Bin Yunus, Mohammed K.
A1 Radey, Rani N.
A1 Hamad, Asalah F.
A1 Beyari, Hatoon T.
A1 Alharazi, Shahad S.
YR 2024
UL http://smj.org.sa/content/45/3/261.abstract
AB Objectives: To examine the prevalence of menstrual irregularities, side effects, and discontinuation rates of etonogestrel subdermal implants (ESI) in women attending King Abdulaziz Medical City, Jeddah, Saudi Arabia.Methods: This cross-sectional was carried out based on electronic medical records and a phone-based questionnaire administered to women who underwent ESI insertion in a single tertiary care hospital in Jeddah, Saudi Arabia, between 2019 and 2022. The primary objective was the prevalence of menstrual abnormalities. The secondary study objective included the discontinuation rate, reasons for discontinuation, and ESI side effects.Results: In total, 345 women with ESI were included in this study. The prevalence of any type of menstrual abnormalities was 88%. Other side effects included skin and mood changes, arm pain, and numbness. The discontinuation rate was 11% in the first year and 22% before the completion of 36 months.Conclusion: Although menstrual abnormalities are a common side effect of ESI, only 22% of users discontinued this method of contraception.